Business Description
Cerus Corp
NAICS : 339112
SIC : 3845
ISIN : US1570851014
Share Class Description:
CERS: Ordinary SharesTotal Employee Number:
345Description
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.83 | |||||
Equity-to-Asset | 0.3 | |||||
Debt-to-Equity | 1.44 | |||||
Debt-to-EBITDA | 204.96 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -3.03 | |||||
Beneish M-Score | -2.63 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.6 | |||||
3-Year EBITDA Growth Rate | 46.6 | |||||
3-Year EPS without NRI Growth Rate | 31.9 | |||||
3-Year Book Growth Rate | -4.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 11.07 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.64 | |||||
9-Day RSI | 63.25 | |||||
14-Day RSI | 62.83 | |||||
3-1 Month Momentum % | 35.45 | |||||
6-1 Month Momentum % | 24.27 | |||||
12-1 Month Momentum % | 65.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.63 | |||||
Quick Ratio | 1.06 | |||||
Cash Ratio | 0.75 | |||||
Days Inventory | 195.81 | |||||
Days Sales Outstanding | 49.62 | |||||
Days Payable | 102.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.7 | |||||
Shareholder Yield % | 0.11 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 52.99 | |||||
Operating Margin % | -1.47 | |||||
Net Margin % | -4.41 | |||||
EBITDA Margin % | 0.22 | |||||
FCF Margin % | -0.56 | |||||
OCF Margin % | 1.22 | |||||
ROE % | -15.7 | |||||
ROA % | -4.42 | |||||
ROIC % | -3.06 | |||||
3-Year ROIIC % | -228.42 | |||||
ROC (Joel Greenblatt) % | -1.99 | |||||
ROCE % | -0.87 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2.78 | |||||
PB Ratio | 9.18 | |||||
Price-to-Tangible-Book | 9.47 | |||||
Price-to-Operating-Cash-Flow | 240.03 | |||||
EV-to-EBIT | -589.2 | |||||
EV-to-EBITDA | 1353.29 | |||||
EV-to-Revenue | 2.97 | |||||
EV-to-FCF | -527.76 | |||||
Price-to-GF-Value | 1.38 | |||||
Price-to-Median-PS-Value | 0.33 | |||||
| Price-to-Net-Current-Asset-Value | 31.25 | |||||
Earnings Yield (Greenblatt) % | -0.17 | |||||
FCF Yield % | -0.19 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CERS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cerus Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 216.555 | ||
| EPS (TTM) ($) | -0.05 | ||
| Beta | 2.9898 | ||
| 3-Year Sharpe Ratio | 0.34 | ||
| 3-Year Sortino Ratio | 0.56 | ||
| Volatility % | 68.55 | ||
| 14-Day RSI | 62.83 | ||
| 14-Day ATR ($) | 0.183127 | ||
| 20-Day SMA ($) | 2.85025 | ||
| 12-1 Month Momentum % | 65.16 | ||
| 52-Week Range ($) | 1.15 - 3.4698 | ||
| Shares Outstanding (Mil) | 200.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cerus Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cerus Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 119 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 118 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 16:30 | In 26 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 25 days | ||
| General meeting for 2026 | 2026-06-02 09:00 | 2.84 (-6.27%) | ||
| First quarter earnings conference call for 2026 | 2026-04-30 16:30 | 1.92 (-2.54%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 1.92 (-2.54%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-03 10:30 | 2.53 (-1.56%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-02 16:30 | 2.56 (-1.35%) | ||
| Annual report for 2025 | 2026-03-02 | 2.56 (-1.35%) |
Show
Entries
Cerus Corp Frequently Asked Questions
What is Cerus Corp(CERS)'s stock price today?
The current price of CERS is $3.13. The 52 week high of CERS is $3.47 and 52 week low is $1.15.
When is next earnings date of Cerus Corp(CERS)?
The next earnings date of Cerus Corp(CERS) is 2026-08-05 Est..
Does Cerus Corp(CERS) pay dividends? If so, how much?
Cerus Corp(CERS) does not pay dividend.
Guru Commentaries on NAS:CERS
No articles.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers